$ News

Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders

Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights

Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency

Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks

Inozyme Pharma to Present at Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Piper Sandler Sticks to Its Buy Rating for Inozyme Pharma (INZY)

Analysts’ Top Healthcare Picks: Inozyme Pharma (INZY), Tyra Bioscience (TYRA)

Promising Clinical Trial Results Justify Buy Rating for Inozyme Pharma

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)

Optimistic Outlook on Inozyme Pharma’s INZ-701 Backed by Promising Trial Data and Market Potential

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

Inozyme announces ‘positive’ interim data from ongoing Phase 1 SEAPORT 1 trial

Inozyme announces 'positive' interim data from ongoing Phase 1 SEAPORT 1 trial

Inozyme Pharma Reports Promising Results in SEAPORT 1 Trial